FRANKFURT, Germany, May 13, 2011 /PRNewswire-FirstCall/ --
- Reaxys is an Online Workflow Solution Used byResearch Chemists in Lead Identification to Fuel Their Drug Discovery Processes
Elsevier, the world's leading publisher of scientific content and online solutions announced today that Syngene, India's first
Dr. Manoj Nerurkar, Head of Small Molecule Discovery & Development at Syngene, said of the agreement, "It's critical for our scientists to have immediate access to the relevant chemical information. We have to generate maximum output with a minimum number of experiments. The insights Reaxys gives us into possible synthetic routes and validated physical property data is crucial in ensuring that when we start in the lab we will generate better output in less time. Starting with Reaxys, we can be sure that the information is reliable and we will not be led down any false routes."
Syngene is already a preferred research service provider to leading players in global pharmaceutical and chemical industries who continue to invest and commit to enlarging their R&D activities in India. Access to Reaxys' validated, curated chemical information will be a key factor in helping Syngene maintain this position.
"Reaxys is dedicated to providing the relevant information that will enable researchers to innovate effectively: to act immediately on their findings from Reaxys and apply them directly in the lab," said Mark van Mierle, Managing Director, Pharma and Biotech Group, Elsevier. "We are pleased to extend our relationship with Syngene and we look forward to continuing to support it in its ongoing R&D efforts."
Established in 1994, Biocon subsidiary Syngene is an internationally reputed contract research and manufacturing organisation with multidisciplinary skills in chemistry, biology, process development and scale-up, formulation and analytical development and preclinical services. India's first Contract Research Organization (CRO), it has successfully partnered with leading players in global pharmaceutical, biotechnology, chemical and agrochemical industries across a wide range of discovery and development programmes.
From early stage discovery and process development through to cGMP manufacturing, it provides customised services to pharmaceutical and biotechnology majors on a strong platform of confidentiality and intellectual property protection. Its deep scientific talent pool and state-of-the-art R&D and production facilities enable it to enhance productivity and accelerate delivery of all projects with the highest degree of professionalism.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com/) and Cell (http://www.cell.com/), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect (http://www.sciencedirect.com/), SciVerse Scopus (http://www.scopus.com/home.url), Reaxys (https://www.reaxys.com/info/), MD Consult (http://www.mdconsult.com/php/244261459-272/homepage) and Nursing Consult ( http://confidenceconnected.com/login/consult?env=PROD&URI=/nursing/index), which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com/) and MEDai's Pinpoint Review (http://www.medai.com/), which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier ( http://www.elsevier.com/wps/find/homepage.cws_home) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC ( http://www.reedelsevier.com/Pages/Home.aspx), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media Contact Tom Reller Vice President, Global Corporate Relations +1-215-239-3508 T.Reller@Elsevier.com
Subscribe to our Free Newsletters!
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...
Video-electroencephalography monitoring is a diagnostic technique that records the electrical ...
Myomectomy is a surgery that is done to remove fibroids, which are non-cancerous growths of the ...View All